Professor HemePath @TataMemorial Leukemia Researcher, Genomics, Bioinformatics, Method Development, MRD, cfDNA, AI/ML, 🎸Music 🐕Dad who tweets about 😎 science
Tata Memorial Center, Mumbai
Joined September 2009
- Tweets4.5K
- Following691
- Followers2.5K
- Likes7.4K
The Hugging face incident
Who cares.... right?
Instadocs:AI gone wild (27 min only)
You should be scared about AGI means
What is the end game for OpenAI and Anthropic and all of them
Why AI need regulatory oversight worldwide 😰
Nikhil Patkar retweeted
Heartiest congratulations @npaesa! A long, arduous process that you led brilliantly. A pleasure to contribute to this consensus, aligned with the vision of @GTumors, & work with all co-authors and respondents..Thnx to all members of @usioffice & @urosogo for their participation
101 experts from 25 countries | New international consensus published in Urologic Oncology.
I am pleased to share our recent publication in Urologic Oncology Seminars and Original Investigations :
“Project international Delphi consensus recommendations for perioperative management of inguinal lymphadenectomy in cancer patients”.
Developed within the Penile Cancer Optimization Initiative (PeCOI), @GTumors and @CAU_URO , this study addresses the prevention and management of perioperative complications following inguinal lymphadenectomy, an area where considerable variability in clinical practice remains.
Key findings:
* 101 experts from 25 countries, representing a broad international and multidisciplinary panel.
* 86 clinical statements evaluated through a two-round modified Delphi process.
* Consensus achieved on 51 statements (59.3%), covering preoperative optimization, lymphatic complications, drain management, antibiotic and thromboembolic prophylaxis, wound complications, and functional rehabilitation.
* Identification of areas of clinical uncertainty requiring further research and prospective validation.
This study provides practical, consensus-based recommendations to support the standardization of perioperative care in inguinal lymphadenectomy, particularly relevant in penile cancer, where high-quality evidence remains limited.
It has been a privilege to work alongside such an outstanding group of internationally recognized experts, @LuisMedinaMD, @drmarcostobias , @jteoh_hk , Amandeep Arora , @drgaganprakash , @DoctorSotelo , and @SpiessPhilippe , as well as all the specialists who contributed to this international consensus.
My sincere thanks to everyone involved, with special thanks to Philippe Spiess, Marcos Tobias-Machado, @ARRODRIGUEZMD , and Luis G. Medina for their support and trust throughout this project.
🙏 @dr_romero_otero @JustoQuintas @RicardoBrime @DrFelixGuerrero @DavidCarracedoC @TouijerKarim @rojo_esther @DrGhaliBelkahia Belkahia Clara Briand Barriga @José Miguel Pérez Ruiz Facundo Barrientos Moll Agustín Fraile Poblador @ROC_Urologia
Published in: Urologic Oncology: Seminars and Original Investigations, 2026.
Full article: lnkd.in/e_zvaRpQ
#UrologicOncology #PenileCancer #PeCOI #DelphiConsensus #InternationalCollaboration #ROCClinic
Nikhil Patkar retweeted
Italian pride🇮🇹🇮🇹🇮🇹
In a trial involving adults with Ph-positive acute lymphoblastic leukemia, 24-month event-free survival was 86% with the TKI–immunotherapy combination ponatinib–blinatumomab and 67% with imatinib plus chemotherapy. Full phase 3 GIMEMA ALL2820 trial results: nej.md/4scorw0
Editorial: Chemotherapy-free Treatment of Ph-Positive ALL nej.md/3VIVUC8
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL.” The graph shows event-free survival (the primary end point) in the intention-to-treat analysis among patients in the intervention group (who received ponatinib plus blinatumomab) and in the control group (who received imatinib plus chemotherapy). The trial name, GIMEMA ALL2820, is in parentheses after the title. The NEJM identity sits at the bottom.
Such an important topic!
nature.com/articles/s41592-0…
Nikhil Patkar retweeted
Right on @isliquidbiopsy 🙌🏻
Time for change….
We don’t often think about the utility of liquid biopsy (cfDNA) in myeloid malignancies but it certainly has a role, particularly for capturing the molecular heterogeneity of extramedullary disease.
Read our recent @BCD_AACR paper here for more on this topic.
aacrjournals.org/bloodcancer…
🧬 New in Blood Cancer Discovery: multiomic profiling of myeloid sarcoma reveals distinct extramedullary clonal evolution, transcriptional adaptation, and recurrent RAS pathway activation.
Importantly, ctDNA sequencing captured the molecular composition of myeloid sarcoma, supporting a potential noninvasive approach to profiling extramedullary AML.
@ManelEsteller @ChristianRolfo @UmbertoMalapel1 @ElJanLe @drgandara @MJOSESERRANO19 @ChristianRolfo @RobertoBoreaMD @ErulEnes @ReduzziCarol @ddemiguelperez @PasqualePisapia @BenBleibergMD @Al3ssandroRusso @ESaldanhaMD @eleonora_nicolo @DrMirallas @LuisRaezMD @DrYukselUrun
#LiquidBiopsy #ctDNA #AML #MyeloidSarcoma #ISLB
Nikhil Patkar retweeted
Exciting day for DNA Typewriter w/ 2 papers from the lab & SeaHub out today :)
1. Mouse lineage from E0 to E13.5
science.org/doi/10.1126/scie…
2. A fluctuation test for gastruloid heterogeneity
cell.com/cell/fulltext/S0092…
Paper #1 covered in quoted thread. More on paper #2 here. 1/n
Nikhil Patkar retweeted
We're deepening our commitment to scientific research and technological discovery by committing $150 million to the Genesis Mission.
We'll also make Claude and our technical support available to more than 15 federal agencies.
anthropic.com/news/genesis-m…
Nikhil Patkar retweeted
Childhood cancer is not merely a disease we treat—it is a disease we can cure with early diagnosis, timely treatment, and equitable access to care.
The goal is not just better survival, but a future where no child is denied the chance to be cured. 💛
Nikhil Patkar retweeted
Yann LeCun's (@ylecun ) latest talk at ETH Zürich
Scaling LLMs to reach AGI is "impossible"
A large language model is trained on about 30 trillion tokens, which is roughly 10^14 bytes of text and would take a person about 400,000 years to read.
A 4-year-old child receives about the same amount of data, 10^14 bytes, through vision alone in about 1 year and 10 months.
In his view, intelligence is the ability to learn new tasks quickly or perform them without prior training, as a teenager learns to drive in about 20 hours. Scaling increases stored knowledge, but it does not produce this ability to adapt.
----
From "Perfology Clips" YouTube channel, (link in comment)
New discovery comes ‘close’ to test biology’s central dogma epaper.thehindu.com/ccidist-…
Nikhil Patkar retweeted
Should prostatic adenocarcinoma, 3+3 be renamed prostatic acinar neoplasm? Pathologists battle it out in Hairy Cell Potter and the Order of the Prostate @MountSinai_Path #pathologists
Nikhil Patkar retweeted
BREAKING NEWS
The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”
Nikhil Patkar retweeted
Excited to share our new study describing uRARE-seq, a tumor-naive #LiquidBiopsy method for analyzing urine cell-free RNA (cfRNA) in #BladderCancer and other genitourinary cancers. Out today in @NatureMedicine 🧵 1/16 rdcu.be/bRoXk7REWtRa
Nikhil Patkar retweeted
Excited to introduce uRARE-Seq for detection and monitoring of bladder cancers and beyond.
Eager to see how this new liquid biopsy tool can change the course of these diseases and overcome the unmet needs of patients with these challenging genitourinary cancers.
@Kevinjliu_ @max_diehn @StanfordMed @StanfordCancer @stanfordcbio
nature.com/articles/s41591-0…
Nikhil Patkar retweeted
Is this a way to interview grieving parents (even if their child was actually doing something unauthorized in a mere exam)?
Where is the commonsense and decency?
Where does this bravado go when it comes to interviewing politicians and bureaucrats who fail to do their jobs?
#TheBuckStopsHere: "Don't know what he had in his hand" — Sahil's parents on exam CCTV row. Watch
@PadmajaJoshi
Nikhil Patkar retweeted
MECOM rearrangement = high-risk disease, regardless of blast count?
A national registry study from Thailand examined 1,248 myeloid neoplasms and identified 15 cases with MECOM rearrangements.
- MECOM rearrangements were rare: 0.9% of AML and 3% of MDS
- Outcomes were poor, with a 1-year survival of only 27.5%
- Among AML cases treated with intensive 7+3 chemotherapy, none achieved complete remission
- In contrast, all 3 MDS patients treated with hypomethylating agents achieved a complete haematological response
- One patient who subsequently underwent allogeneic stem cell transplantation achieved durable remission
The bigger picture:
The similarly poor survival across lower- and higher-blast disease supports recognizing MECOM-rearranged myeloid neoplasms as a biologically high-risk entity and is not one defined simply by blast percentage.
📖 Read more in linked article: bit.ly/4z9LYjZ.
#JCPJournal #Hematopathology #MECOM #AML #MDS #MyeloidNeoplasms #Leukemia #MolecularPathology #Pathology #Hematology
